Comparison of the chronic effects of alpha-chlordane and pp' DDT on the level of cerebral amino acids and free ammonia in mice

Milacemide increases 5-hydroxytryptamine and dopamine levels in rat brain--possible mechanisms of milacemide antimyoclonic property in the p,p'-DDT-induced myoclonus

Milacemide, a glycine prodrug that is able to enter the brain readily, has been shown to have an antimyoclonic property in the p,p'-DDT-induced myoclonus syndrome. Milacemide increased regional 5-HT and dopamine and decreased 5-HIAA, DOPAC and HVA levels in naive rats. In p,p'-DDT-treated rats, 5-HT levels were unchanged at the time the rats experienced spontaneous myoclonus in all brain regions except in the striatum, where it increased. 5-HIAA levels increased but did not reach significant levels except in the striatum. Dopamine, DOPAC, HVA and norepinephrine were unchanged. When rats were treated concurrently with both p,p'-DDT and milacemide, regional 5-HT levels were increased and NE levels in the brainstem and cerebellum decreased. Depletion of brain serotonin by pretreatment with PCPA or with 5,7-DHT, or blocking 5-HT receptors with different 5-HT antagonists, failed to eliminate the antimyoclonic property of milacemide. This antimyoclonic effect of milacemide may be mediated through other mechanisms besides its ability to increase brain 5-HT levels. Possible mechanisms to be considered are its antiepileptic property, and its ability to increase brain glycine levels. Milacemide may have potential for therapeutic trials in patients with myoclonus.

Glycine involvement in DDT-induced myoclonus

The DDT syndrome in rats consists of tremor, myoclonus, running seizures, hyperthermia, episodic boxing, and excessive grooming. DDT did not change whole-brain glycine levels when the rats had stimulus-sensitive myoclonus, spontaneous myoclonus, or seizures. However, regional analysis showed a decrease in glycine levels in the pons and medulla initially, but they rose again despite worsening of the myoclonus. Glycine given intraventricularly and the glycine prodrug, milacemide, given intraperitoneally suppressed DDT-induced myoclonus. A dose of milacemide that prevented DDT-induced myoclonus caused a significant increase in glycine levels in cortex, septum accumbens, cerebellum, striatum, hippocampus diencephalon, midbrain, pons, and medulla. The increase was most marked in the forebrain structures. There was no change in serine levels in these areas. These data suggest that the glycinergic system may be playing an important role in the manifestation of DDT-induced myoclonus.

The alterations of rat brain GABA and glutamine induced by the organophosphorus compound cyolane

Levels of the amino acids GABA and glutamine were determined in the whole brain of the white albino rat Rattus norvegicus after daily injection of 1/2, 1/4, 1/8, 1/16, 1/32 and 1/100 LD50 of cyolane. With 1/2 LD50 an increase in the level of both GABA and glutamine in the brain was recorded. Dose levels of 1/4 and 1/8 LD50 caused an increase in the level of GABA and a decrease in glutamine concentration followed by an increase from the 7th and 11th days for 1/4 and 1/8 LD50, respectively. The induced increase in GABA level started from the 2nd week for 1/16 and 1/32 LD50 and from the 3rd week for 1/100 LD50. Dose levels of 1/16, 1/32 and 1/100 LD50 caused a fluctuating increase in glutamine concentration starting from the 2nd, 3rd and 6th weeks, respectively, which was followed by a fluctuating decrease at the 9th week for 1/32 and 1/100 LD50. These findings support previous findings that the enhanced transformation of glutamic acid to GABA and glutamine is a result of a disturbance in the metabolism of the glutamic acid-GABA and the glutamic acid-glutamine systems in the rat brain.